Nevro Corp. (NVRO)
USD 3.74
(-7.65%)
USD 3.74
(-7.65%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -92.21 Million USD | -3172.74% |
| 2022 | 3 Million USD | 102.28% |
| 2021 | -131.36 Million USD | -58.14% |
| 2020 | -83.06 Million USD | 19.89% |
| 2019 | -103.68 Million USD | -110.72% |
| 2018 | -49.2 Million USD | -34.23% |
| 2017 | -36.65 Million USD | -15.36% |
| 2016 | -31.77 Million USD | 52.87% |
| 2015 | -67.43 Million USD | -119.79% |
| 2014 | -30.68 Million USD | -17.94% |
| 2013 | -26.01 Million USD | -37.15% |
| 2012 | -18.96 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -19.57 Million USD | 22.96% |
| 2024 Q1 | -25.4 Million USD | -182.92% |
| 2023 Q4 | -8.98 Million USD | 61.75% |
| 2023 Q3 | -23.47 Million USD | 5.04% |
| 2023 FY | -92.21 Million USD | -3172.74% |
| 2023 Q1 | -35.02 Million USD | -82.52% |
| 2023 Q2 | -24.72 Million USD | 29.42% |
| 2022 Q4 | -19.19 Million USD | -123.55% |
| 2022 Q2 | -24.99 Million USD | 27.2% |
| 2022 Q1 | -34.32 Million USD | -13.91% |
| 2022 FY | 3 Million USD | 102.28% |
| 2022 Q3 | 81.5 Million USD | 426.16% |
| 2021 Q2 | -21.59 Million USD | 26.96% |
| 2021 FY | -131.36 Million USD | -58.14% |
| 2021 Q3 | -50.07 Million USD | -131.94% |
| 2021 Q1 | -29.56 Million USD | -314.66% |
| 2021 Q4 | -30.13 Million USD | 39.82% |
| 2020 Q4 | -7.12 Million USD | 28.6% |
| 2020 Q3 | -9.98 Million USD | 75.68% |
| 2020 Q2 | -41.06 Million USD | -64.99% |
| 2020 FY | -83.06 Million USD | 19.89% |
| 2020 Q1 | -24.88 Million USD | -81.11% |
| 2019 Q3 | -17.84 Million USD | 36.31% |
| 2019 Q2 | -28.02 Million USD | 36.43% |
| 2019 Q1 | -44.07 Million USD | -358.79% |
| 2019 FY | -103.68 Million USD | -110.72% |
| 2019 Q4 | -13.74 Million USD | 23.0% |
| 2018 Q2 | -10.62 Million USD | 40.04% |
| 2018 Q3 | -11.26 Million USD | -6.07% |
| 2018 Q4 | -9.6 Million USD | 14.72% |
| 2018 FY | -49.2 Million USD | -34.23% |
| 2018 Q1 | -17.71 Million USD | -310.88% |
| 2017 Q2 | -11.61 Million USD | 19.97% |
| 2017 FY | -36.65 Million USD | -15.36% |
| 2017 Q4 | -4.31 Million USD | 30.8% |
| 2017 Q3 | -6.23 Million USD | 46.34% |
| 2017 Q1 | -14.5 Million USD | -47.65% |
| 2016 Q1 | -9.28 Million USD | 34.55% |
| 2016 Q2 | -8.77 Million USD | 5.48% |
| 2016 Q3 | -3.88 Million USD | 55.74% |
| 2016 FY | -31.77 Million USD | 52.87% |
| 2016 Q4 | -9.82 Million USD | -152.83% |
| 2015 Q4 | -14.19 Million USD | 27.05% |
| 2015 Q3 | -19.45 Million USD | 1.38% |
| 2015 Q2 | -19.72 Million USD | -40.3% |
| 2015 Q1 | -14.06 Million USD | -69.19% |
| 2015 FY | -67.43 Million USD | -119.79% |
| 2014 Q1 | -7.05 Million USD | -4.69% |
| 2014 FY | -30.68 Million USD | -17.94% |
| 2014 Q4 | -8.31 Million USD | -5.39% |
| 2014 Q3 | -7.88 Million USD | -6.14% |
| 2014 Q2 | -7.42 Million USD | -5.29% |
| 2013 Q3 | -5.01 Million USD | 27.62% |
| 2013 FY | -26.01 Million USD | -37.15% |
| 2013 Q4 | -6.74 Million USD | -34.37% |
| 2013 Q1 | -7.39 Million USD | 0.0% |
| 2013 Q2 | -6.93 Million USD | 6.34% |
| 2012 FY | -18.96 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Abbott Laboratories | 5.72 Billion USD | 101.611% |
| Allurion Technologies Inc. | -82.3 Million USD | -12.04% |
| Artivion, Inc. | -30.69 Million USD | -200.466% |
| Avanos Medical, Inc. | -61.8 Million USD | -49.212% |
| Butterfly Network, Inc. | -133.69 Million USD | 31.03% |
| Butterfly Network, Inc. | -133.69 Million USD | 31.03% |
| Bio-Rad Laboratories, Inc. | -637.32 Million USD | 85.531% |
| Boston Scientific Corporation | 1.59 Billion USD | 105.789% |
| Perspective Therapeutics, Inc. | -14.67 Million USD | -528.582% |
| CONMED Corporation | 64.45 Million USD | 243.057% |
| Edwards Lifesciences Corporation | 1.4 Billion USD | 106.575% |
| Paragon 28, Inc. | -47.84 Million USD | -92.749% |
| Glaukos Corporation | -134.66 Million USD | 31.522% |
| Globus Medical, Inc. | 122.87 Million USD | 175.047% |
| Inspire Medical Systems, Inc. | -21.15 Million USD | -335.933% |
| Integer Holdings Corporation | 90.65 Million USD | 201.724% |
| Medtronic plc | 3.67 Billion USD | 102.509% |
| Owlet, Inc. | -32.9 Million USD | -180.274% |
| Penumbra, Inc. | 90.95 Million USD | 201.384% |
| Vicarious Surgical Inc. | -71.07 Million USD | -29.748% |
| Smith & Nephew plc | 263 Million USD | 135.062% |
| Sonendo, Inc. | -60.91 Million USD | -51.37% |
| STERIS plc | 378.23 Million USD | 124.38% |
| Stryker Corporation | 3.16 Billion USD | 102.914% |
| Vapotherm, Inc. | -58.19 Million USD | -58.461% |
| Zimmer Biomet Holdings, Inc. | 1.02 Billion USD | 109.005% |